Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory

[News]

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

More... (http://www.news-medical.net/news/20120602/Lapatinib-pazopanib-combination-therapy-not-beneficial-for-patients-with-inflammatory-breast-cancer.aspx)